Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $175.00

Merck & Co., Inc. (NYSE:MRK) had its target price raised by analysts at UBS Group from $145.00 to $175.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price indicates a potential upside of 15.34% from the company’s previous close.

Several other equities research analysts also recently commented on the stock. Jefferies Financial Group downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $150.00 target price (up from $142.00) on shares of Merck & Co., Inc. in a report on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $140.70.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK traded down $0.47 during midday trading on Thursday, hitting $151.73. 6,239,130 shares of the company’s stock were exchanged, compared to its average volume of 10,764,729. The company’s 50 day moving average price is $126.86 and its 200 day moving average price is $120.74. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $153.50. The firm has a market capitalization of $374.34 billion, a PE ratio of 121.38, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $26,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Graney & King LLC lifted its position in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized mRNA cancer vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a Phase 3 melanoma trial. The regimen significantly extended recurrence-free survival and reduced the risk of cancer spreading compared with Keytruda alone—the first positive late-stage result for an mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The results strengthen Merck’s longer-term oncology pipeline and could help offset concerns about Keytruda’s expected patent expiration later this decade. The companies see potential use in thousands of high-risk melanoma patients, subject to additional data and regulatory approval targeted for 2027, while related trials are evaluating other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Morgan Stanley upgraded MRK from “equal weight” to “overweight” and raised its price target to $179 from $116, implying substantial potential upside based on the reported valuation. Merck analyst upgrade
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating but lifted its target to $150 from $142, indicating limited near-term upside and a more cautious view of the vaccine opportunity. Royal Bank of Canada rating update
• Neutral Sentiment: Unusually heavy options activity, including a sharp increase in call purchases, suggests heightened speculative interest following the trial announcement, but does not necessarily indicate sustained fundamental demand.
• Negative Sentiment: Jefferies downgraded Merck from “strong-buy” to “hold,” reflecting potential profit-taking and uncertainty about the vaccine’s eventual approval, commercial adoption, pricing, and contribution relative to Keytruda’s mature revenue base. Jefferies rating update

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.